Skip to content
Research Article Open access CC BY 4.0

The Efficacy of Remdesivir Drug to Control the Recently Emerged Novel Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2): A Review Study

Humera Batool, Mizba Baksh, Khatja Batool, Zainab Rafique, Sibghatullah Shahab, Ghulam Muhammad Humayun

Journal of Advances in Microbiology · pp. 1–8 · Published 7 Dec 2020

10.9734/jamb/2020/v20i1130294

Abstract

Introduction: Remdesivir is among the investigational drugs which show some promising effect against COVID-19, it may be due to its broad-spectrum antiviral action against some RNA viruses. To date very few clinical studies have been conducted on the use of remdesivir to the treatment of COVID-19. The main objective of the present study was, to conduct a review on the effect of Remdesivir to the treatment of COVID-19. To the best of our knowledge, this is the first systematic review on the effect of remdesivir drug to the treatment of COVID-19. Methodology: We have searched PubMed, for published studies on assessing the effect of remdesivir drug among patients with confirmed COVID-19. The main search terms used were “COVID-19” or “SARS-CoV-2”, “remdesivir”, and “systematic review”. Results: Only 11 research articles were found eligible for enclosure in this systematic review, among selected studies only two were randomized, placebo-controlled trial of intravenous remdesivir. Data on the efficacy of remdesivir in the patients with confirmed COVID-19 from clinical Phase-III trials are still pending. Recently, in the latter half of May month, results of two hospital based randomized, double-blind, placebo-controlled phase III trials studies were reported, both the studies found that remdesivir was efficient in the treatment of patients with confirmed COVID-19. However, Wang et al., (2020) found that remdesivir treatment was not significantly associated with clinical benefits. Conclusion: From the systematic review, the use of remdesivir to cure patients with confirms COVID-19 was found promising; however, further clinical studies with large patient size need to be considered. The efficacy and safety of remdesivir in the treatment of COVID-19 will require to be emphasized in future research studies.

COVID-19 SARS-CoV-2 antiviral drug remdesivir treatment.

References (19)

  1. 1 A novel coronavirus outbreak of global health concern [DOI]
  2. 2 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
  3. 3 The trinity of COVID-19: immunity, inflammation and intervention [DOI]
  4. 4 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [DOI]
  5. 5 Compassionate Use of Remdesivir for Patients with Severe Covid-19 [DOI]
  6. 6 Coronavirus Disease 2019–COVID-19 [DOI]
  7. 7 Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [DOI]
  8. 8 Remdesivir for the Treatment of Covid-19 — Preliminary Report [DOI]
  9. 9 Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency [DOI]
  10. 10 The hallmarks of COVID-19 disease [DOI]
  11. 11 Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence [DOI]
  12. 12 Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics [DOI]
  13. 13 Current epidemiological and clinical features of COVID-19; a global perspective from China [DOI]
  14. 14 Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 [DOI]
  15. 15 Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19 [DOI]
  16. 16 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review [DOI]
  17. 17 Efficacy of Remdesivir in COVID-19 [DOI]
  18. 18 Current Epidemiological and Clinical Features of COVID-19; a Global Perspective From China [DOI]
  19. 19 First 12 patients with coronavirus disease 2019 (COVID-19) in the United States [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.